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Abstract
Melatonin (N-acetyl-5-methoxytryptamine, MLT) is a neuroendocrine hormone, which is primarily synthesized by the
pineal gland in vertebrates. Melatonin is a remarkable molecule with diverse biological and physiological actions
and is involved in the regulation of various important functions such as circadian rhythm, energy metabolism, the
reproductive system, the cardiovascular system, and the neuropsychiatric system. It also plays a role in disease by
having anti-neoplastic and anti-osteoarthritic effects among others. Recently, research has focused on the roles of
melatonin in oxidative stress, lipid metabolism, and hepatic steatosis and its potential therapeutic roles.
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Introduction
Melatonin is a neuroendocrine hormone secreted by
the pineal gland [1]. In mammals, the synthesis of
melatonin is initiated by the transformation of trypto-
phan to 5-Hydroxytryptamine. 5-Hydroxytryptamine is
converted into N-acetyl-5-hydroxytryptamine catalyzed
by aralkylamine-N-acetyrltransferase (AANAT). After
several additional reactions it is finally converted into
N-acetyl-5-methoxytryptamine (Fig. 1) catalyzed by
hydroxyindole O-methyltransferase (HIOMT) and this
finally indole product is termed melatonin [2]. The syn-
thesis and secretion of melatonin is regulated by light
intensity [3]. Variations in light intensity stimulate the
retinal ganglion cells to depolarize which stimulates the
hypothalamic suprachiasmatic nucleus via the optic nerve.
The hypothalamic suprachiasmatic nucleus releases
adrenaline through the postsynaptic ganglion net, thus
functioning in the pineal gland. Ultimately, the expres-
sion and activity of AANAT enzyme in pineal gland is
up or down-regulated, and regulates the synthetic and
secretion of melatonin.
Research has shown that [4] there is an obvious circa-
dian rhythm in the blood levels of melatonin in verte-
brates, with levels being higher at night and lower during
the day. After synthesis, melatonin is released into the
cerebrospinal fluid and blood immediately and then is dis-
tributed throughout the body in the systemic circulation.
Biological function
Since it was discovered in 1958 [5] melatonin has become
a hotspot for biomedical research. Initially, it was found
that melatonin functions to regulate the sleep cycle, and
melatonin production has been linked to the so-called
‘strong’ circadian oscillator [6].
Further investigations found that melatonin also has
anti-tumor effects [7]. Melatonin can exert both direct
and indirect anti-neoplastic effects in factorial synergy
with other differentiating, anti-proliferative, immune-
modulating and trophic molecules that form part of the
anticancer treatment formulated by Luigi Di Bella [8]. The
interaction between melatonin and the DBM (Di Bella
Method, DBM: somatostatin, retinoids, ascorbic acid, vita-
min D3, prolactin inhibitors, chondroitin-sulfate) mole-
cules counters the multiple processes that characterize the
neoplastic process (induction, promotion, progression
and/or dissemination, tumoral genetic mutation).
Melatonin also functions in the regulation of immunity
[9], resistance to ionizing radiation [10], and protection
against free radicals and oxidative stress [11]. It also pro-
tects against ischemia-reperfusion injury after myocar-
dial [12]. Further research has shown that it can regulate
lipid and glucose metabolism [13–15].
Two types of melatonin receptors have been identified
melatonin membrane receptor (MMR) and melatonin
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nuclear receptor (MNR). There are three types of mela-
tonin membrane receptors which have been named
MT1, MT2, MT3. Among them, both MTl and MT2 are
G-protein-coupled receptors, which are widely distrib-
uted in the nervous, cardiovascular, immune, and repro-
ductive systems. [16, 17] MT3, which is also called
chinone reductase-2, belongs to the reductase family. It
has been found in various tissues and organs in mam-
mals [18]. MT3 can inhibit the generation of reactive
oxygen species (ROS) in mitochondria by preventing the
entry of reducing equivalents from chinone into the
electron transport chain. The melatonin nuclear receptor
isretinoid Z receptor alpha (RORa/RZR), but its function
is still unclear. Moreover, melatonin has also been found
to be a highly fat soluble hormone, which can enter cells
independently of membrane receptors and bind with nu-
clear receptors or other transcription factors [19].
Antioxidation function
Melatonin is a strong antioxidant and acts as a free radical
scavenger [20]. It can scavenger superoxide (O−), hydro-
gen peroxide (H202), hydroxyl radicals (OH
.), organic per-
oxy radicals (ROO.), singlet oxygen (102), nitric oxide
(NO.), peroxynitrite (ONOO−), and hypochlorous acid.
Melatonin can activate antioxidant enzymes [21], and can
regulate gene transcription of antioxidant enzymes [22]. In
a study adriamycin provoked lipid peroxidation and subse-
quent induction of oxidative-stress related genes were
down-regulated reflecting the reduced oxidative stress in
livers of the melatonin treated animals [23]. Melatonin
can stimulate the secretion and activity of glutathione
synthase [24], glutathione peroxidase(GSH-Px), gluta-
thione reductase(GSH-Rd), catalase(CAT), AND glucose-
6-phosphate dehydrogenase [25, 26]. Melatonin also causes
a significant reduction in oxidative stress by reducing
plasma malondialdehyde (MDA) levels and an increase in
plasma superoxide dismutase (SOD) levels [27]. Melatonin
can down-regulate the expression of some enzymes which
increase oxidative stress such as nitric oxide synthase
(NOS) [28]. Melatonin treatment abrogated oxidative
stress in the liver of aged rats by preventing of the de-
creased activity of CAT and the downregulation of
Cu,Zn-SOD and GPx gene expression [29]. It can augment
the activity of other antioxidants [30] and protect antioxi-
dant enzymes from oxidative damage [31], Melatonin acts
on the mitochondrial respiratory chain decreasing electron
leak and lowers the generation of free radicals [32].
Melatonin can also increase the synthesis of ATP [33].
Anti-inflammatory function
Many studies have found that melatonin has anti-
inflammatory effects. Experiments using melatonin as a
pharmaceutical agent were mainly in vitro studies where
melatonin doses exceeding the nocturnal plasma levels
are required to exert clear effects. At supra-physiological
concentrations, melatonin induces T-cell proliferation
and up-regulation of pro-inflammatory cytokines [34, 35].
Hu et al. found that melatonin treatment significantly de-
creased the severity of hepatic cell damage, steatosis and
the immigration of inflammatory cells, reduced serum and
tissue inflammatory cytokines levels, tissue lipid peroxida-
tion, neutrophil infiltration and inhibited the apoptosis
of hepatocytes in an alcohol-induced hepatic injury
mice model [36]. Exogenous melatonin administration
increases the proliferative response of rat lymphocytes
[37], increases the number of NK cells [38], stimulates
the pro-inflammatory cytokines IL-1 and TNF-α [39, 40]
and enhances phagocytosis [41]. Melatonin exerts a
concentration-dependent effect on the immune system.
Indeed, increasing concentrations of melatonin induce
Fig. 1 The molecular structure melatonin
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T-cell proliferation in a dose-dependent way. In addition,
it was demonstrated that pharmacological doses of mela-
tonin inhibit
INF-γ production at concentrations of 0.1–1 mM
[42, 43]. In some systems, the modulation of apoptosis
requires high melatonin doses [44, 45]. Whether or not
these effects have physiological significance, occurring
as a paracrine or autocrine response, i.e., in microenviron-
ments with an elevated melatonin concentration like in
the bone marrow, is currently being investigated. In any
case, these findings demonstrate that melatonin is a
potential exogenous pharmacological modulator of the
inflammatory response.
Effects on insulin resistance
Recent studies have confirmed the presence of the mela-
tonin membrane receptors MT1 and MT2 in human
pancreatic tissue and the islets of Langerhans [46]. The
expression of melatonin receptors in patients with
T2DM was demonstrated in immunohistochemical stud-
ies [47]. It was found that melatonin receptors on pancre-
atic β-cells are involved in three parallel signaling
pathways, which have different effects on insulin secretion.
In terms of insulin release, the insulin-inhibiting action of
melatonin is mediated by the dominantly expressed MT1
receptor through activation of Gi-coupled adenylate
cyclase activity, thereby negatively modulating incretin-
induced increase in 3’, 5’-cyclic adenosine monopho-
sphate (cAMP). Likewise, it was also demonstrated that
melatonin inhibits the 3’, 5’-cyclicguanosine monopho-
sphate (cGMP) signaling pathway and, consequently,
insulin secretion possibly in a MT2 receptor mediated
fashion. Meanwhile, melatonin-dependent IP3 release
may play a role in the short-term support of other IP3-
releasing agents, like acetylcholine, or may be related to
the long-term regulation of pancreaticcell functions
which may affect insulin secretion [15]. All of these
studies support the concept that melatonin plays an
important role in the regulation of insulin secretion
and glucose/lipid metabolism.
Effect of melatonin on lipid metabolism
Along with the increased understanding of the functions
of melatonin, more research has focused on the effects
of melatonin on lipid metabolism and hepatic steatosis.
Early animal experiments showed that high fat diet in-
duced hyperlipidemia [48]. Melatonin treatment for three
months can significantly reduce serum total cholesterol
(TC) and low density lipoprotein (LDL-C) levels and re-
markably increase high density lipoprotein (HDL-C) [49].
Long-term treatment with melatonin(1.1 mg/day for
30 weeks)can significantly reduce the liver lipid content in
type 2 diabetic rats. Melatonin administration to Otsuka
Long-Evans Tokushima Fatty(OLETF)rats reduced the
hypertriglyceridemia by 39 % and hyperinsulinemia by
33 % and also restored hepatic delta-5 desaturase (an
enzyme which aid in insulin secretion) activity by
148 %. Research on high-fat diet (HFD)-induced obesity
in animal models has showed that [27] compared with
an untreated obese group and a lean control group,
melatonin treatment for four weeks causes a statisti-
cally significant decrease in serum lipids, an increase in
GSH-PX and HDL, and reversal of fatty changes in the
liver and atherosclerotic changes in the blood vessels.
These studies suggest that exogenous melatonin admin-
istration has effects on lipid metabolism and provides
the basis for additional research.
Subsequently, researches in human subjects also con-
firmed the beneficial effect of melatonin on lipid metabol-
ism. Kadmin et al. reported that dyslipidemia was
improved in patients with type 2 diabetes after treatment
with melatonin [50]. This study was designed to evaluate
the effects of melatonin and zinc on the lipid metabolism
and renal function in type 2 DM patients poorly con-
trolled with metformin. A placebo-controlled, double-
blind clinical trial was performed in which 46 type 2
diabetic patients were selected and allocated into three
groups. These groups were treated with single daily oral
doses of both 10 mg melatonin and 50 mg zinc acetate or
10 mg of melatonin and 50 mg of zinc acetate in addition
to the regularly used metformin or placebo over a period
of 90 days. Fasting lipid profiles and microalbuminuria
(MAU) were measured before initiating the treatments
(zero time) and after 30 and 90 days of treatment. Daily
administration of melatonin and zinc improved lipid me-
tabolism and decreased levels of MAU as well as improv-
ing the response to metformin.
Kozirog M et al. found that melatonin treatment im-
proves lipid metabolism in patients with metabolic syn-
drome [51]. Melatonin administered for 2 months
(5 mg/day, 2 hr before bedtime) significantly improved
lipid profile (decrease in low-density lipoprotein cholesterol
149.7 ± 26.4 versus 139.9 ± 30.2 mg/dL, P < 0.05) and also
lowered blood pressure (systolic blood pressure - 132.8 ±
9.8 versus 120.5 ± 11.0 mmHg, P < 0.001, diastolic blood
pressure - 81.7 ± 8.8 versus 75 ± 7.4 mmHg, P < 0.01).
Effect of melatonin on liver fat accumulation
Research has shown that liver steatosis can lead to insu-
lin resistance as well as dysfunction of glucose and lipid
metabolism. Nonalcoholic fatty liver disease (NAFLD) is
an early reversible accumulation which can lead to stea-
tohepatitis and has recently been the subject of a consid-
erable amount of research. Pan et al. [52] found that
melatonin ameliorates NAFLD induced by a high-fat diet
in rats. A high-fat diet leads to oxidative stress with ex-
tensive liver steatosis in rats. Melatonin reduced hepatic
steatosis and inflammation by lowering serum AST,
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ALT, liver total cholesterol, and triglycerides in high-fat
diet fed rats.
Further studies have suggested that melatonin can de-
crease hepatocyte apoptosis [53]. Methionine- and
choline-deficient diet-induced nonalcoholic steatohepati-
tis rats were treated with melatonin (50 mg/kg/day, in-
traperitoneally) for one month. It was observed that
melatonin decreased oxidative stress, levels of proinflam-
matory cytokines, and hepatocyte apoptosis.
A study on high-fat-diet rats by Gregorios Hatzis et al.
[54] found that compared to untreated group, the two
treated groups with different doses of melatonin (5 or
10 mg/kg) both had decreased mean liver weights
(−5.0 g and −4.9 g) (P < 0.001) and lower weight ratios of
liver weight to body (−1.0 %) (P < 0.001). Rats fed a high
fat diet treated with melatonin showed significantly less
steatosis. The group treated with 10 mg/kg melatonin
exhibited grade III steatosis in 1 of 29 (3.4 %) rats, while
the group treated with 5 mg/kg melatonin exhibited
grade III steatosis in 3 of 27 (11.1 %) rats. However,
melatonin could not reverse established steatosis.
Celinski et al. demonstrated the effect of melatonin on
patients with NAFLD [55]. Essentiale with tryptophan (2 x
500 mg/day) or melatonin (2 x 5 mg/day) for 14 months
both have a significant reduction in the activity of gamma-
glutamyl transferase (GGPT) and levels of triglycerides and
LDL-cholesterol comparing with the control group treated
with Essentiale forte only. In the liver biopsies performed
before and after treatment, melatonin and tryptophan re-
duced macrovesicular steatosis and lobular inflammation,
while there was no change in control group.
Possible mechanisms
While the true mechanism of action of melatonin on
lipid accumulation remains under investigation, several
theories have been suggested.
Lipid peroxidation and lipid membrane peroxidation
contribute to the progression from steatosis to steatohepa-
titis, liver cell necrosis, necroinflammation, elevated trans-
aminases, and fibrosis [56]. However, steatosis would not
progress to steatohepatitis and fibrosis were it not for the
contribution of free radicals and oxidative stress [57, 58].
Inhibition of the electron transport chain could lead to the
generation of superoxide, which is capable of initiating
lipid peroxidation and the generation of addition oxidative
stress [59]. Melatonin can significantly reduce the activa-
tion of LPS-induced sterol regulatory element-binding
protein (SREBP)-1c, as well as the expression of SREBP-
1c target genes which can prevent LPS-induced hepatic
lipid accumulation [60]. In this respect, as a free radical
scavenger, melatonin may have additive effects on the re-
duction of lipid peroxidation.
Fig. 2 Possible mechanism of action of melatonin on improving dyslipidemia and hepatic steatosis. (O− = superoxide; H202 = hydrogen peroxide;
OH. = hydroxyl radicals; ROO. = organic peroxy radicals; 102= singlet oxygen ; NO
. = nitric oxide; ONOO− = nitric oxide; GSH-Px = glutathione
peroxidase; GSH-Rd = glutathione reductase; CAT = catalase; G6PD = glucose-6-phosphate dehydrogenase; SOD = superoxide dismutase;
MDA=malondialdehyde; NOS = nitric oxide synthase; SREBP-1c = sterol regulatory element-binding protein-1c; IL-1β= interleukin-1β; IL-6 = interleukin-6;
TNF-α = Tumor Necrosis Factor-α; NK = Natural Killer; IL-1 = interleukin-1; ALT = Alanine transaminase; AST = Aspertate Aminotransferase;
TC = total cholesterol; TG = Triglyceride; LDL-C = low density lipoprotein; HDL-C = high density lipoprotein.)
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The mechanism of liver injury was found to be related
to increased levels of pro-inflammatory cytokines, oxida-
tive stress, and pro-apoptotic factors. Liver steatosis and
apoptosis were found to occur in methionine-, choline-
and folate-deficient diet rats, which is considered to be
related to inflammation [61]. Melatonin can prevent
liver damage by inducing the hepatic apoptotic index in
these methionine-, choline- and folate-deficient diet rats
model. Through increasing the migration of inflamma-
tory cells and their activation, oxidative stress plays an
important role in the development of liver inflammation.
Methane Dicarboxylic Aldehyde (MDA), the final prod-
uct of lipid peroxidation, has been shown to be closely
related to the level of inflammation [62]. In a recent
study by Kireev et al. [63], it was observed that mela-
tonin can protect the liver of aged ovariectomized rats
from pro-inflammatory and oxidative damage. Com-
pared with untreated rats in the control group, both the
two melatonin-treated groups of intact and ovariecto-
mized rats demonstrated a significant reduction in the
level of oxidative stress; decreased levels of IL-1β, IL-6,
TNF-α, and also decreased transaminases, and tissue
MDA. However, the melatonin treated groups demon-
strated increased levels SOD and GSH. Melatonin’s
efficacy on the biochemical and histopathological
markers of the liver damage is probably associated
with its anti-inflammatory effects (Fig. 2).
Conclusion
In conclusion, melatonin has significant anti-oxidation
and anti-inflammatory activities. In various studies in
animals and human, melatonin has been shown to be
beneficial not only in lipid metabolism, but also in im-
proving liver fat accumulation and insulin resistance as
well. As a regulator of various systems, melatonin may
prove to be an important therapeutic choiceto improve
dyslipidemia and hepatic steatosis.
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